Monday, December 2 | 8:00 a.m.-8:10 a.m. | M1-SSBR03-1 | Room S404
Attendees will get to see the results of supplemental imaging techniques from the Breast Screening - Risk Adaptive Imaging for Density (BRAID) Trial in this session.
Fiona Gilbert, MD, from the University of Cambridge in England will present her team’s findings, which show that contrast imaging techniques are more sensitive while also having higher recall rates than automated breast ultrasound (ABUS).
The BRAID trial is attempting to find out whether extra scans with one of several scan types is helpful in diagnosing breast cancer in women with dense breast tissue. Recruitment for the trial began in 2019 and ended in 2024.
Gilbert and colleagues compared supplemental imaging techniques following a negative screening mammogram in women with dense breasts in a UK breast screening program. They included 9,366 women ages 50 to 70 years with BI-RADS density C and D and negative 2D mammograms. The women were randomly assorted to abbreviated MRI (n = 2,318), ABUS (2,253), contrast-enhanced mammography (CEM, n = 2,242), or standard of care arms (n = 2,553) at 10 UK health centers.
The researchers found that intention to treat cancer detection rates per 1,000 were 10.8 for abbreviated MRI, 4.0 for ABUS, and 13.8 for CEM. The recall rates for these modalities were 9.5%, 4.1%, and 9.4%, respectively.
The team found 57 invasive cancers with and without ductal carcinoma in situ (DCIS) and 14 DCIS-alone cases. Additionally, the median invasive cancer size was 10 mm for abbreviated MRI, 9 mm for ABUS, and 12 mm for CEM, respectively.
Finally, all ABUS-detected cancers were invasive while the proportions of invasive cancers in CEM and abbreviated MRI were 79% and 74%, respectively.
Find out how these insights could help with early breast cancer detection by attending this session.
